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Abstract The vasculature serves as the main conduit for
breast tumor metastases and is a target of therapeutics in
many tumor types. In this study, we aimed to determine if
tumor-associated vascular properties could help to explain
the differences observed in metastagenicity across the
intrinsic subtypes of human breast tumors. Analysis of
gene expression signatures from more than 3,000 human
breast tumors found that genomic programs that measured
vascular quantity, vascular proliferation, and a VEGF/
Hypoxia-signature were the most highly expressed in
claudin-low and basal-like tumors. The majority of the
vascular gene signatures added metastasis-predictive
information to immunohistochemistry-defined microvessel
density scores and genomically defined-intrinsic subtype
classification. Interestingly, pure claudin-low cell lines, and
subsets of claudin-low-like cells within established basal-
like cancer cell lines, exhibited endothelial/tube-like mor-
phology when cultured on Matrigel. In vivo xenografts
found that claudin-low tumors, but not luminal tumors,
extensively perfused injected contrast agent through para-
cellular spaces and non-vascular tumor-lined channels.
Taken together, the endothelial-like characteristics of the
cancer cells, combined with both the amount and the
physiologic state of the vasculature contribute to breast
cancer metastatic progression. We hypothesize that the
genetic signatures we have identified highlight patients that
should respond most favorably to anti-vascular agents.
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Introduction
There are at least five genomically distinct subtypes of
human breast tumors [1, 2]. Each tumor subtype interacts
with endothelial cells (EC) via secreted factors and directly
by cell–cell contact (reviewed in [3]). These associations
facilitate cancer cell entry into blood- and lymphatic-ves-
sels, which initiates the metastatic cascade and results in
the death of *400,000 people worldwide each year [4].
The dependence of primary tumor growth on angiogenesis
was first proposed over 40 years ago [5], and since then the
amount of histologically defined vasculature within a
tumor has been shown to be correlated with tumor meta-
static potential in nearly all solid cancer types [6–8].
We recently reported that the estrogen receptor (ER)
negative basal-like and claudin-low tumor subtypes are
likely to spread to vital organs such as the brain and lung;
without targeted therapies, HER2-enriched tumors
aggressively colonize the liver, while ER?/luminal A and
luminal B tumors are slower to disseminate and are usually
first identified in the bone [9]. It is possible that some
breast cancer subtypes are predisposed to metastasize more
readily than others due to the amount of vasculature present
within and surrounding the primary tumor. Therefore, we
hypothesized that basal-like and claudin-low tumors, as
compared to luminal tumors, preferentially attract
increased numbers of blood- and lymphatic-endothelial
cells (BEC, LEC, collectively EC), which facilitates their
metastasis via vessel association, intra/extravasation and
dissemination. Alternatively, there may be no major dif-
ference in the amount of vasculature present within dif-
ferent subtypes, but instead, the physiologic properties of
the cancer cells regulate how different subtypes interact
with ECs.
To identify vascular contributions to breast tumor met-
astatic progression, we identify and contrast multiple dis-
tinct EC gene expression programs in comparison with
known clinical variables and other published genomic
signatures. We have found vascular gene expression sig-
natures that add metastasis-predicting information to
pathologically-defined microvessel density scores. In
addition, we also find that the different breast cancer sub-
types not only vary in their expression of endothelial genes,
but further, that these genomic programs result in perme-
ability of the vasculature in claudin-low tumors.
Materials and methods
Cell culture and imaging experiments
The human breast cancer cell lines were maintained in
standard growth media (ATCC: MCF-7, T47D, SKBR3,
MDA231) in RPMI (Gibco) plus 10 % FBS (Sigma) and
PenStrep (Gibco); Asterland SUM149, SUM159 in
Ham’s F-12 (Gibco) plus 5 % FBS (Sigma), insulin (Gibco
5ug/mL), and hydrocortisone (Gibco 1ug/mL). Human
endothelial cells (EC) were all purchased from Lonza and
were grown in EBM-2 media with BulletKit additives
(Lonza CC-3202). Blood microvascular endothelial cells
(BEC) and lymphatic microvascular endothelial cells (LEC)
were from the same donor, and along with HUVECs, were
all used within 5 passages. All vascular cell lines were
grown in EBM-2 for 48 h prior to RNA extraction (mono-
cultures and cocultures). Three-dimensional morphology
experiments were performed by coating a Lab-Tek 8-well
chamber slide (Thermo Scientific) with 125 uL of Matrigel
(Becton–Dickinson) and then plating 50,000 cells in each
well. To allow for discrimination of cancer cells and ECs,
they were labeled with Sigma’s PKH67 (green) and PKH26
(red) dyes, respectively, prior to co-culture. All morpho-
logical studies (Fig. 4C–E) were performed for 18 h. Ima-
ges of cell culture experiments were taken with a Nikon
inverted phase contrast microscope and recorded with
OpenLab software (Fig. 4; Supplemental Fig. 2). Confocal
images (Fig. 4E) were taken with an Olympus FV 500
Confocal Laser Scanning Microscope and processed with
Olympus FluoView software. Immunofluorescence images
of xenografts tumors were acquired with an Olympus IX81
Inverted Light Microscope. All fluorescence images were
combined with Image J v1.46.
Gene expression microarrays and gene signatures
RNA was prepared from human breast cancer cell lines and
ECs with Qiagen’s RNeasy mini kit. Gene expression
microarrays were performed according to established pro-
tocols [10, 11], with all microarray data publicly available
at the UNC microarray database (UNCMD) https://
genome.unc.edu/. New microarrays have been deposited
in the Gene Expression Omnibus under the accession
number GSE37145, with previously published data avail-
able under GSE31870. Prior to analyses, the expression
data were downloaded from the UNCMD, and the probes
were filtered by requiring the Lowess normalized intensity
values in both sample and control to be greater than 10 dpi
and present on more than 70 % of microarrays. The nor-
malized log2 ratios (Cy5 sample/Cy3 control) of probes
mapping to the same Entrez gene ID were averaged and
median centered to obtain the final dataset.
For the vascular content signature, RNA was prepared
from human breast cancer cell lines (MCF7, T47D,
SKBR3, SUM149, SUM159, MDA231), endothelial cells
(HUVEC, LEC, BEC) and commercial RNA for human
tissue was obtained from Ambion (brain; AM6050), (lung;
AM7968), (liver; AM7960), (lymph node; AM7894),
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Clontech (bone marrow; 636591), and Biochain (bone
marrow; R1234024-10). The breast cancer cell line arrays
and the human organ arrays were compared against endo-
thelial cell arrays from BEC, LEC, and HUVEC in a two-
class SAM. Genes with high expression were used to
generate this signature.
The activated endothelium signature was generated from
microarrays of BEC and LEC RNA that had been grown in
monoculture or transwell co-cultured with cancer cells. For
transwell co-culture, 200,000 endothelial cells were plated
into a well of a 6-well plate, then a transwell filter with
0.4 micron pores (Corning) was inserted into the wells and
200,000 cancer cells were added to the upper compartment in
EBM-2. After 48 h the transwell inserts were removed and
the endothelial cell RNA was extracted (Qiagen). For the
activated endothelium signature a two-class SAM was per-
formed on triplicate BEC and LEC arrays compared to arrays
from BECs and LECs that had each been transwell cultured
with the six breast cancer cell lines described above. Each
tumor’s endothelial signature score was determined by
averaging the log2 expression values for all genes in the
signature (either 74 for vascular content, or 110 for activated
endothelium) that were also found in the different test
datasets. To separate out the proliferation component of the
signature, all genes with a Pearson correlation value greater
than 0.5 to a 11-gene proliferation signature [12] were con-
sidered proliferation related; due to the reduced number of
genes present, this signature was not able to be divided in the
merged 550 tumor dataset. Lastly, a mouse mammary tumor
gene expression dataset was also examined that has been
previously published [13] (GSE3165 and GSE27101).
Statistics and data analysis
All statistical tests were performed with WinSTAT, R
v2.15.1, and Cluster v3.0.
In vivo tumor studies and immunofluorescence
All animal procedures were done under a protocol approved
by the University of North Carolina Animal Care and Use
Committee. To establish MCF-7, MDA-231, SUM159
tumors, 3 Nod scid gamma (NOD.Cg-Prkdcscid IL2rgtm1Wjl/
SzJ JAX) mice for each tumor type were anesthetized with
isoflurane, and one-million cells in 100 % Matrigel with
growth factors (Becton–Dickinson) were injected into the
lactiferous duct of the fourth (inguinal) mammary gland. For
MCF-7 tumors, mice were also implanted with an estradiol-
releasing silastic pellet as previously described [14]. MDA-
231 and SUM159 tumors were grown for 18 days, MCF-7
tumors were grown for 24 days. The difference in growth
times reflects the amount of time needed to extract similar
sized tumors. All tumors were removed when they were
*7 9 7 mm. To label perfusing vasculature in vivo, mice
were injected with 1 mg of Texas red-conjugated dextran
(molecular weight 70,000; Invitrogen/Molecular Probes,
Eugene, OR) diluted in PBS (5 mg/mL) and then euthanized
5 min later, as previously described [15]. Prior to being
embedded and frozen in Optimal Cutting Temperature
(OCT) Compound, tissues were fixed in 10 % formalin
overnight, and then 30 % sucrose overnight. Tissues were
then stored at -80 C until they were cut into 9–10 micron
thick sections. Primary antibodies utilized were from Dako
(vWF (A0082)), Novus Biosciences (LYVE1 [NBP1-
43411], vimentin [NBP2-12472], cytokeratin 19 [NB100-
79916]), Novacastra (CD34 [NCL-L-END]), and Santa Cruz
(PECAM [sc-101454]). Secondary antibodies were from
Molecular Probes/Life Technologies (Goat anti-rabbit 488)
and Jackson ImmunoResearch (donkey anti-rat FITC).
Mounting media containing DAPI was from Invitrogen
(P36931).
Results
Vascular genomic programs are highly expressed
in claudin-low and basal-like tumors
The majority of nearly one-hundred publications have
found that high microvessel density is associated with poor
prognosis in breast cancer [16]. Since the results from this
assay can vary depending on the vascular antibody utilized
and/or one’s definition of a vascular hot-spot, we aimed to
determine if vascular gene expression signatures could
serve as an alternative biomarker to identify patients with
an increased likelihood of distant metastasis or death. To
test this hypothesis, we developed two novel Endothelial
Cell (EC)-derived signatures and also tested a published
EC signature that has been shown to be specific for the
microvasculature [17]. For comparisons of these signa-
tures, we used five previously published microarray data
sets of breast cancer patients; these analyses comprised
[3,000 human breast tumors with *10 % overlap [2, 9,
18–20]. To contrast how the vascular signatures were
expressed in normal breast samples, breast tumors, and
pure endothelial cell lines, we determined average gene
expression signature scores for each sample and in three
EC lines (HUVEC, BEC, and LEC). To visualize these
values across different subtypes of human breast tumors,
normal breast samples, and EC lines, each sample’s sig-
nature was plotted as box-and-whisker plots (Fig. 1). On
average, expression of the Wallgard et al. vascular signa-
ture was highest in EC lines, followed by normal breast
reduction mammoplasty tissues (Fig. 1A). Interestingly,
the claudin-low tumors had the highest vasculature signa-
ture expression when compared against any of the other
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tumor subtypes (t test, p \ 0.0001). When this signature
was examined on a database of mouse mammary tumors
and normal mammary glands [13], the normal mammary
tissue and murine claudin-low tumors also exhibited high
expression (Fig. 1A).
We next generated a new vascular-specific signature that
was designed to be completely distinct from mammary
cells. We performed two-class significance analysis of
microarrays (SAM) analyses on gene expression data from
HUVECs, BECs, and LECs compared against organs that
often harbor breast tumor metastases (bone marrow, brain,
liver, lymph node, lung) and human breast cancer cells that
represent multiple intrinsic subtypes (MCF-7, T47D,
SKBR3, SUM149, SUM159, MDA-MB-231). This analy-
sis identified 74 significantly upregulated genes in ECs
(false discovery rate, FDR\0.05) (Supplemental Table 1).
An Ingenuity pathway analysis of these genes identified the
top biological functions to include cardiovascular system
development, cancer, and cellular movement. This gene
signature, hence forth called the ‘vascular content’ signa-
ture, is presented in Fig. 1B. This signature was also most
highly expressed in claudin-low tumors as compared to
other tumor subtypes (t-test, p \ 0.0001), and compared to
the Wallgard et al. signature this signature showed a larger
separation between breast samples and ECs. The highest
expression of the vascular content signature was observed
in claudin-low mouse tumors (Fig. 1B). Interestingly, only
two genes from our 74-gene vascular content signature
overlapped with the 58 genes from Wallgard et al. (EGFL7
and ESAM). We propose that the reason the normal breast
samples have relatively higher levels of both the Wallgard
et al. and vascular content signature are due to the rela-
tively high endothelial content found in a normal breast.
We next sought to identify genes that change in ECs in
response to signals from cancer cells. Thus, to evaluate a
cancer-stimulated or ‘activated endothelium’ signature, we
performed gene expression analyses on co-cultures of
cancer cells and ECs. To identify common pathways
involved in EC activation (independent of tumor subtype),
we utilized different subtypes of cancer cells and generated
a single signature of cancer cell-stimulated ECs. In these
assays, the cancer cells and ECs exchanged secreted factors
by being bathed in the same media, but both remained
physically separated (see Methods). After 48 h of co-cul-
ture, a two-class SAM identified 110 genes that were sig-
nificantly upregulated in ECs that had been transwell
cultured with cancer cells as compared to ECs grown in
monoculture (Supplemental Table 2) (FDR \ 0.05). This
signature was distinct from the previous two vascular
profiles as determined by gene overlap, with one gene
overlapping with the Wallgard et al. signature (SLCO2A1)
and one gene overlapping with the vascular content sig-
nature (CYP1A1). Ingenuity Analysis identified top
networks as cell cycle, cellular growth and proliferation,
and lipid metabolism. This ‘activated endothelium’ signa-
ture was highest in basal-like tumors (t-test; p \ 0.03
compared to claudin-low tumors) and strikingly under-
expressed in normal mouse mammary tissues and mono-
cultures of human ECs (Fig. 1C). Interestingly, recent
immunohistochemical and magnetic resonance imaging
studies have found that heightened vascular proliferation
occurs in basal-like breast cancers [21, 22].
Lastly, we aimed to contrast the information provided by
these genetic programs with a distant metastasis associated
VEGF/hypoxia signature from Hu et al. [23]; this signature
was the most highly expressed in basal-like (t-test; p \ 0.02
compared to claudin-low tumors) and claudin-low tumors
(Fig. 1D) and only had one gene overlap with any of the other
signatures (PLOD1; vascular content).
The tumor-activated endothelium signature identifies
proliferating vasculature
We next sought to directly compare each endothelial sig-
nature to several other vascular signatures that have been
previously identified [17, 23–25]. Pearson correlations
were determined between the various signatures and a
known cell proliferation signature [12] using the same five
breast cancer datasets. Other than the Tumor Vascular A
signature [24], as a whole, most vascular signatures were
positively correlated (Fig. 2). We also found that the acti-
vated endothelium signature showed a strong correlation
with proliferation (0.57–0.71). We therefore ‘separated’ the
proliferation component from the rest of the activated
endothelium signature by identifying genes with a Pearson
correlation greater than 0.5 to the proliferation signature
[26]. This resulted in two distinct signatures: an ‘activated
endothelium proliferation component’ and an ‘activated
endothelium non-proliferation component’ (Supplemental
Fig. 1). In each of the datasets tested, the vascular content,
Wallgard et al., and vasculogenic mimicry signatures were
all correlated ([0.5), suggesting that these three signatures
were tracking similar biological processes. The VEGF/
hypoxia signature showed positive correlations with acti-
vated endothelium; interestingly, both the proliferative and
non-proliferative components of the activated endothelium
signature had smaller Pearson correlations with the VEGF/
hypoxia signature than the complete activated endothelium
signature, indicating that the VEGF/hypoxia signature
identifies both of these biological processes.
Vascular signatures add metastasis predictive
information within intrinsic subtypes
To determine if the expression of any of the vascular sig-
natures correlated with increased metastasis in vivo,
36 Clin Exp Metastasis (2014) 31:33–45
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Fig. 1 Vascular gene expression signatures in different intrinsic
subtypes of human breast tumors and transgenic mouse models of
mammary cancer. Box-and-whisker plots are shown for five human
breast tumor datasets (Left) and a mouse mammary tumor dataset [13]
(Right). Gene expression signature scores were identified for endo-
thelial cell lines (BEC, LEC, HUVEC), each breast cancer dataset,
and then combined for display in the following order within each
subtype; Combined 855 [9], MDACC [20], Merged 550 [19],
METABRIC [18], UNC [2]. a Wallgard et al., b vascular content,
c activated endothelium, and d VEGF/hypoxia signatures. The log2
mean signature expression for each tumor is shown as a cross, the bar
indicates the median value, whiskers show the range within subtype
and are the 1.5 * inter-quartile range
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univariate Cox proportional hazards models analyses were
performed for each signature on the five datasets (Sup-
plemental Table 3). Several variables individually were
able to significantly predict metastatic relapse in every
dataset, including the luminal B and basal-like subtype
status (as compared to luminal A), ER status, activated
endothelium (including both the proliferation and non-
proliferation components), VEGF/hypoxia, vasculogenic
mimicry, and the 11-gene proliferation signature. We next
used multivariate Cox proportional hazards models to
determine if any of the vascular signatures provided addi-
tional prognostic information in addition to intrinsic
subtype classification. In these analyses, each vascular
signature was individually tested against the metastasis
predicting information contained within intrinsic subtype
status; note that only the vascular signature information is
shown in Table 1. Interestingly, both the activated endo-
thelium and VEGF/hypoxia signatures were the only two
signatures that were found to be significant in all datasets.
Therefore these signatures can be used to identify partic-
ularly aggressive subsets of tumors within a given intrinsic
subtype (the full table including intrinsic subtype infor-
mation is shown in Supplemental Table 4). These findings
support the conclusion that the quality of endothelium and
Fig. 2 Assessment of the relatedness of vascular gene expression signatures. Shown are Pearson correlation coefficients of gene expression
signatures from the five breast cancer datasets. Positive values are colored red and negative values are green
38 Clin Exp Metastasis (2014) 31:33–45
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the specific heterotypic interactions between endothelium
and epithelium are both important components of meta-
static progression.
Vascular signatures add metastasis predictive
information to microvessel density scores
We next aimed to understand if any of the vascular gene
expression signatures were a surrogate for the histology-
based microvessel density (MVD) assay. Therefore, MVD
scores were determined on a 70-tumor dataset that had also
been subjected to gene expression microarrays (UNC70)
(Supplemental Table 5). Although the sample set was
small, on average MVD was similar across the breast
cancer subtypes, except in the normal-like tumors which
are comprised mostly of normal breast tissues (Fig. 3A). In
this dataset, high MVD was significantly associated with
decreased relapse free survival in a univariate analysis
when tested as a continuous variable (p = 0.04), and was
also trending towards significance in Kaplan–Meier anal-
yses when the sample set was divided into halves based
upon the rank order expression of this gene set (p = 0.06)
(Fig. 3B). When tested in multivariate Cox proportional
hazard models along with intrinsic subtype classification,
MVD scores significantly contributed metastasis prediction
information (p = 0.04).
Interestingly, additional multivariate analyses found that
the gene signatures for vascular content, activated endo-
thelium non-proliferation component, and VEGF/hypoxia
all independently added metastasis-predictive information
to the MVD scores (p \ 0.05), unlike the proliferation
related signatures (PAM50 11-gene proliferation signature
and the activated endothelium proliferation component
signature; p \ 0.3). Similar results were also found with
Kaplan–Meier plots shown in Fig. 3C–E. In these analyses,
in contrast to proliferation which did not significantly help
to stratify aggressive tumors (Fig. 3C), the additional
prognostic information provided by the endothelial signa-
tures when combined with MVD scores (Fig. 3D, E),
inform us that using both the MVD scores and either of
these two EC signatures are better than using either method
individually.
Claudin-low breast cancer cell lines have endothelial
characteristics
We next aimed to elucidate why claudin-low tumors had
the highest expression of the gene signatures that were
designed to measure total endothelial quantity: Wallgard
et al., vascular content, and activated endothelium non-
proliferation component (Fig. 1; Supplemental Fig. 1). We
reasoned that high vascular signature scores could either be
attributed to the amount of vasculature present in these
tumors, or due to the extent in which claudin-low breast
cancer cells express endothelial genes. Since, the MVD
scores suggest similar amounts of vasculature across the
subtypes as assessed histologically (Fig. 3A), we hypoth-
esized that claudin-low tumor cells themselves may
express these vascular cell associated genes. Therefore, we
identified vascular signature scores for the human breast
cancer cell lines presented in Neve et al. [2, 27.] and found
that the vascular content gene expression signature was
most predominately expressed in claudin-low as compared
to basal-like (p \ 0.01) or luminal (p \ 0.001) breast
cancer cell lines (Fig. 4A). To further test the hypothesis
that claudin-low cell lines have endothelial cell character-
istics, we performed unsupervised hierarchical clustering
using gene expression data from six breast cancer cell lines
Table 1 Multivariate analyses of the vascular signatures tested
individually against intrinsic subtype for metastasis prediction; tested
in the five breast tumor datasets. Bolded signatures added metastasis
predicting information to intrinsic subtype classification. Full table is
presented in Supplemental Table 4
Signature Combined 855 UNC 254 METABRIC 1971 MDACC493 MERGED 550
Hazard
ratio
p-Value Hazard
ratio
p-Value Hazard
ratio
p-Value Hazard
ratio
p-Value Hazard
ratio
p-Value
Proliferation 1.428 5.26E-02 1.365 1.61E-01 1.242 1.97E-07 1.186 2.57E-01 1.259 1.08E-02
Wallgard 1.266 2.23E-01 0.913 8.51E-01 1.222 2.02E-02 1.960 4.73E-02 1.169 5.16E-01
Vascular content 1.985 8.66E-05 1.666 4.23E-01 1.192 2.07E-01 1.274 4.67E-01 2.555 2.51E-04
Vasculogenic mimicry 1.450 8.80E-04 1.300 4.53E-01 1.278 1.70E-03 1.570 2.40E-02 1.720 8.50E-04
VEGF hypoxia 1.439 1.73E-06 3.255 2.16E-07 1.262 1.51E-07 1.609 1.54E-02 1.760 3.45E-06
Tumor vascular A 1.263 2.65E-01 0.128 1.46E-02 1.286 3.20E-02 0.291 6.12E-03 0.879 6.42E-01
Tumor Vascular B 1.967 1.08E-02 1.081 8.96E-01 1.198 1.64E-01 0.803 6.07E-01 2.220 1.65E-02
Activated endothelium 2.688 3.40E-03 18.406 4.67E-03 2.262 1.40E-03 7.460 2.29E-03 7.942 1.76E-05
Act endo nonproliferation 2.683 5.30E-03 11.021 2.62E-02 1.473 1.38E-01 11.232 4.82E-04 – –
Act endo proliferation 1.106 1.99E-01 1.614 5.96E-02 1.305 4.51E-05 1.035 8.01E-01 – –
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Fig. 3 Gene expression signatures add prognostic information to
immunohistochemistry defined microvessel density scores. a Box-
and-whisker plots are shown for average microvessel density scores
for 70 human breast tumors. b–e Kaplan–Meier plots for relapse free
survival and log-rank test p-values. For testing more than one variable
c–e, tumors were independently ranked from low to high signature
score and then the two groups were combined, which yielded groups
of not necessarily equal number that were reflective of the biology of
the tumor. The p-value in d and e test the tumors with low signature
scores for both variables against all other tumors
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representative of different intrinsic subtypes and blood
vessel endothelial cells (BECs). Interestingly, clustering
with all available expressed genes (12,644) (Fig. 4B), or
the vascular content gene signature (not shown), showed
that claudin-low cell lines (i.e. MDA-MB-231 and
SUM159) are transcriptomically more similar to BECs
than they are to other breast epithelial cancer lines.
Next, we aimed to understand if these expression simi-
larities might also be manifested phenotypically, such as in
tube/chord-like formation that occurs with ECs grown in
three dimensional matrices [28]. To assess this phenotype,
the six breast cancer cell lines and BECs were grown in
Matrigel with EC media. The MDA-MB-231 cell line was
striking in its resemblance to the BECs for tube/loop for-
mation (Fig. 4C). The SUM149 cell line, which is fre-
quently used as a model for inflammatory breast cancer,
and SUM159 cell lines also exhibited tube formation,
which was in contrast to the luminal (MCF7, T47D) and
luminal/HER2-enriched (SKBR3) line that formed irregu-
lar spherical clusters.
Some breast cancer cell lines are cellularly heteroge-
neous and contain mixed populations of cells [2, 29],
therefore, we sorted the basal-like SUM149 cell line into
two distinct populations based on expression of EpCAM
and CD49f [2, 30]. When grown on Matrigel, the Ep-
CAM?/CD49f ? fraction formed cluster-like structures
while the EpCAM-/CD49f ? fraction formed tube-like
structures (Fig. 4D); interestingly, it is the EpCAM-/
CD49f ? fraction that shows the more claudin-low-like
expression features [2]. To determine how different sub-
types of breast cancer cells directly interact with ECs, we
established a two-color three-dimensional co-culture model
with cancer cells and HUVECs (Fig. 4E), or BECs (Sup-
plemental Fig. 2). In co-culture, the luminal and
HER2?lines tended to form cancer cell clumps on top of
the EC loops, while the claudin-low lines interdigitated
with the ECs.
Since claudin-low breast cancers and melanomas share
extensive similarities in gene expression profiles [9, 31],
we were curious if these tube-like structures were remi-
niscent of what has been termed ‘vasculogenic mimicry’
(VM), which was reported first in melanomas [25]. In vitro
we saw no evidence of lumen formation, so it is unlikely
such tube-like structures can actually support blood flow,
but pseudo-vasculature has been interpreted as a survival
strategy arising from genetically pliable tumors [32].
Interestingly, two genes reported to be involved in VM and
pseudo-comedo formation, Ang2/Angpt2 [33] and Cox2/
Ptgs2 [34], are also most highly expressed in claudin-low
tumors (Supplemental Fig. 3). Glioblastoma stem-like cells
have also been shown to exhibit similar phenotypic and
functional features of ECs [35] and ovarian cancer has also
been reported to exhibit VM [36]. Correspondingly, a VM
gene expression signature [25], along with the other two
new vascular signatures discussed above, were also the
most highly expressed in the mesenchymal subtype of
glioblastoma and ovarian cancer [37, 38] (Supplemental
Fig. 4).
High vascular permeability in claudin-low tumors
Given the genomic and morphologic similarities of clau-
din-low cell lines and endothelial cell lines, we next aimed
to determine if tubular structures were formed by claudin-
low cancer cells (Fig. 5A–F), as compared to luminal
cancer cells (Fig. 5G–I), growing in vivo. To identify if
any tube-like structures were able to functionally perfuse
blood, mice were injected intravenously with Texas Red
labeled dextran 5 min before euthanasia [15]. When sub-
jected to pan-endothelial antibodies platelet/endothelial
cell adhesion molecule (PECAM), von Willebrand factor
(vWF), and the lymphatic vessel endothelial hyaluronan
receptor 1 (LYVE1) simultaneously, the claudin-low
tumors were found to have extensive perfusion of dextran
through paracellular spaces (Fig. 5B, E). This heightened
vascular permeability was not observed in the luminal
MCF-7 model (Fig. 5H). Serial frozen sections that utilized
the cancer cell markers vimentin (Fig. 5C, F) or CK19
(Fig. 5I) confirm that the dextran freely diffused through-
out and around the claudin-low tumors but was largely
restricted to the vasculature in luminal tumors.
Discussion
The vasculature interacts directly with breast cancer cells
and facilitates the growth and spread of nearly all human
breast tumors. Since it is well documented that high
microvessel density is associated with increased metastatic
potential in many cancer types [6, 39, 40], which we also
find herein for breast tumors, we hypothesized that vari-
ability in both the total amount of vasculature present, and
the mechanisms used by different types of malignant breast
cells to interact with ECs, may explain why the intrinsic
subtypes metastasize at different rates and to different vital
organs [9, 41, 42]. In these studies, we find that two
independently derived gene signatures that measured the
amount of tumor vasculature were consistently the most
highly expressed in claudin-low tumors. Claudin-low
breast cancer cell lines also expressed elevated levels of
genes found in endothelial cells, exhibited endothelial-like
morphologies when grown in three-dimensional matrices,
and promoted vascular leakiness in vivo. These results
provide evidence that the claudin-low cancer cells them-
selves have endothelial characteristics; qualities which may
facilitate blood brain barrier penetration and metastasis to
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the brain [9, 43]. From these findings, we hypothesize that
the subset of cells that most strongly express the claudin-
low characteristics within a tumor are the cells that initiate
tumor-endothelium interaction, the first step towards suc-
cessful metastasis; the morphological differences observed
with the different populations of SUM149 cells, which also
have different growth rates, support this hypothesis. A
recent paper supports this view and finds that MDA-MB-
231 cells that adhere to the vasculature are Ki67-
negative [44].
Previously, using different three-dimensional model
systems, four distinct morphologies of breast cancer cell
lines have been previously identified; Round, Mass, Grape-
like, and Stellate [45]. Hierarchical clustering of gene
expression microarrays from these cell lines found that
their gene expression profiles largely correlated with their
distinct morphologies and separate into luminal and basal-
like branches of the dendogram. The Basal B subtype [27],
which we refer to largely as claudin-low [2], is morpho-
logically Stellate, whereas the luminal lines are classified
as Round or Mass. The Stellate cell classification (BT-549,
Hs578T, MDA-MB-231, MDA-MB-436) is particularly
interesting for this manuscript since we have found that the
MDA-MB-231 are claudin-low [2] in expression genotype,
and form tubes/chords when grown in endothelial 3D
conditions. The identification that claudin-low breast can-
cer cell lines present with vascular gene expression profiles
and display endothelial-like morphology in 3D culture are
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Fig. 4 Gene expression and morphologic relatedness of endothelial
cells and breast cancer cell lines. a Box-and-whisker plots of vascular
signatures found in human breast cancer cell lines: BL; basal-like,
CL; claudin-low, LUM; luminal. b Unsupervised hierarchical cluster
dendogram of breast cancer cell lines and endothelial cells using all
variably expressed genes (n = 12,644). c Picture of each cell line
after 18 h of 3D culture (95). d Pictures of the FAC sorted SUM149
cell line fractions after 18 h of 3D culture (95). e Pictures of
cocultures after 18 h of 3D culture (95)
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significant because vascular-cancer mosaics have been
found to increase vascular radioresistance [46]. Importantly,
vascular characteristics of tumor cells have also been
described in melanoma [25], ovarian cancer [36], Ewing
sarcoma [47], and more recently in glioblastoma [35, 46].
Like the claudin-low breast cancer subtype that has endo-
thelial/mesenchymal characteristics, both the ovarian and
glioblastoma mesenchymal subtypes show highest expres-
sion of these vascular signatures, including a signature for
vasculogenic mimicry. A previous report identified that
7.9 % of resected breast tumors exhibited vascular mimicry,
which corresponded with an increased rate of hematogenous
recurrence [33]. Interestingly, that report found that vascular
mimicry containing specimens showed significantly higher
Angpt2 expression than non-vascular mimicry tumors. We
evaluated Angpt2 and found that this gene was highly
expressed in claudin-low tumors. A different study found
that cyclooxygenase-2 regulates vascular channel formation
[34]. This gene is also highly expressed in claudin-low
tumors and has been implicated in brain and lung metastasis
[43, 48]. Both of these genes are known to be regulated by
hypoxia. In cancer cells, intratumoral hypoxia generated by
anti-vascular agents Sunitinib and Bevacizumab have been
shown to increase the population of cancer stem cells [49],
and it is the stem-like cells that are the ones most capable of
exhibiting VM [35].
In conclusion, claudin-low tumor cells themselves
exhibit vascular-like gene expression profiles in vivo and
A B C
D E F
G H I
Fig. 5 Identification of paracellular perfusion in claudin-low tumors.
Texas Red Dextran (red) was injected into the circulation of mice
bearing MDA231 (a–c), SUM159 (d–f), or MCF7 (g–i) cells grown as
tumors in vivo. Serial sections for each tumor are shown. Hematox-
ylin and eosin staining (a, d, g); pan-endothelial antibodies vWF/
PECAM/LYVE (green), DAPI (blue), and dextran (red) (b, e, h);
vimentin or cytokeratin 19 cancer cell markers (green), DAPI (blue),
and dextran (red) (c, f, i). Brackets denote extensive dextran perfusion
in the absence of vasculature. All images are 920
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claudin-low breast cancer cell lines, and the claudin-low-
like fractions within basal-like cell lines, also exhibit
endothelial morphologies in vitro. These signatures of EC
phenotypes predict the likelihood of breast tumor metas-
tasis independent of tumor subtype, and also may have
predictive potential for identifying patient cohorts that may
respond to drugs targeting the tumor endothelium.
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